SONY

# Product Data Sheet

## PerCP/Cy5.5 anti-mouse CD38

**Catalog # / Size:** 1113610 / 100 µg
1113605 / 25 µg

**Clone:** 90

**Isotype:** Rat IgG2a, κ

**Immunogen:** Mouse bone marrow pre-B cells

**Reactivity:** Mouse

**Preparation:** The antibody was purified by affinity chromatography and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

**Concentration:** 0.2




C57BL/6 mouse splenocytes were stained with CD38 (clone 90) PerCP/Cy5.5 (filled histogram) or rat IgG2a, κ PerCP/Cy5.5 isotype control (open histogram).

## Applications:

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.125 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.

**Application Notes:** Additional reported applications (for the relevant formats) include: immunohistochemistry[1,2] of acetone-fixed frozen sections, and induction of B cell proliferation1.

**Application References:**
1. Oliver AM, *et al.* 1997. *J. Immunol.* 158:1108.
2. Howard M, *et al.* 1993. *Science* 262:1056.

---

**Description:** CD38 is a 42 kD glycoprotein, also known as T10. It is an ADP-ribosyl hydrolase, expressed on B cells, NK cells, a subset of T cells, brain, muscle, and kidney. In mouse, CD38 expression is downregulated on germinal center B cells and plasma cells, whereas this is not the case for humans. By functioning as both a cyclase and a hydrolase, CD38 mediates lymphocyte activation, as well as adhesion and metabolism of cADPR and NAADP. CD31 is the ligand of CD38.

**Antigen References:**
1. Barclay AN, *et al.* 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Shubinsky G, *et al.* 1997. *Immunity* 7:315.
3. Cesano A, *et al.* 1998. *J. Immunol.* 160:1106.
4. Cockayne DA,